235 related articles for article (PubMed ID: 35242671)
1. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
Xiao Y; Li J; Wu Z; Zhang X; Ming J
Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
[No Abstract] [Full Text] [Related]
3. Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study.
Jiang X; Chen G; Sun L; Liu C; Zhang Y; Liu M; Liu C
Front Oncol; 2022; 12():977226. PubMed ID: 36091103
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
5. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+).
Wang X; Xue Y
Front Endocrinol (Lausanne); 2023; 14():1193592. PubMed ID: 37538790
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
8. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Wei JL; Zhang JX; Fu DY
World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
[TBL] [Abstract][Full Text] [Related]
9. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.
Dou H; Li F; Wang Y; Chen X; Yu P; Jia S; Ba Y; Luo D; Gao T; Li Z; Xiao M
Diagn Pathol; 2024 Jan; 19(1):5. PubMed ID: 38178166
[TBL] [Abstract][Full Text] [Related]
12. Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis.
Lian W; Zheng J; Chen D
Transl Cancer Res; 2020 Oct; 9(10):5969-5978. PubMed ID: 35117209
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
[TBL] [Abstract][Full Text] [Related]
14. Long-term prognostic effect of hormone receptor subtype on breast cancer.
Hwang KT; Kim J; Jung J; Kim BH; Park JH; Jeon SY; Hwang KR; Roh EY; Park JH; Kim SJ
Breast Cancer Res Treat; 2020 Jan; 179(1):139-151. PubMed ID: 31595365
[TBL] [Abstract][Full Text] [Related]
15. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer.
Wang Z; Wang H; Ding X; Chen X; Shen K
Ther Adv Med Oncol; 2020; 12():1758835920932674. PubMed ID: 32550867
[TBL] [Abstract][Full Text] [Related]
16. The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.
Zhao H; Gong Y
Front Oncol; 2021; 11():643956. PubMed ID: 34079755
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
[TBL] [Abstract][Full Text] [Related]
18. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002).
Zheng A; Guo BL; Zhang JG; Jin F;
Chin Med J (Engl); 2021 Jun; 134(13):1569-1575. PubMed ID: 34101635
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study.
Wang M; Liu D; Zhang Z; Dai X; Chen G; Zhu L
Transl Breast Cancer Res; 2023; 4():4. PubMed ID: 38751485
[TBL] [Abstract][Full Text] [Related]
20. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
Senel F
Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
